FLUOGUIDE A/S DK -1 - Asset Resilience Ratio
FLUOGUIDE A/S DK -1 (96X) has an Asset Resilience Ratio of 34.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 96X current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2025–2025)
This chart shows how FLUOGUIDE A/S DK -1's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of FLUOGUIDE A/S DK -1.
Liquid Assets Composition Over Time
This chart breaks down FLUOGUIDE A/S DK -1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read FLUOGUIDE A/S DK -1 total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €30.02 Million | 34.0% |
| Total Liquid Assets | €30.02 Million | 34.00% |
Asset Resilience Insights
- Very High Liquidity: FLUOGUIDE A/S DK -1 maintains exceptional liquid asset reserves at 34.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
FLUOGUIDE A/S DK -1 Industry Peers by Asset Resilience Ratio
Compare FLUOGUIDE A/S DK -1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for FLUOGUIDE A/S DK -1 (2025–2025)
The table below shows the annual Asset Resilience Ratio data for FLUOGUIDE A/S DK -1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.00% | €30.02 Million ≈ $35.09 Million |
€88.29 Million ≈ $103.22 Million |
-- |
About FLUOGUIDE A/S DK -1
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatmen… Read more